Momenta Phama (MNTA) Tops Q3 EPS by 5c

October 31, 2019 7:23 AM EDT
Get Alerts MNTA Hot Sheet
Price: $52.48 --0%

Financial Fact:
Product revenue: 23.34M

Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE

Momenta Phama (NASDAQ: MNTA) reported Q3 EPS of ($0.45), $0.05 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $5.55 million versus the consensus estimate of $5.24 million.

“Our focus in 2019 is on the execution of our clinical programs as they advance toward proof of concept,” said Craig A. Wheeler, President and Chief Executive Officer of Momenta Pharmaceuticals. “Looking ahead to 2020, we anticipate key readouts across our novel auto- and alloimmune programs, including proof-of-concept data from M254 in ITP and nipocalimab in MG. Importantly, both of these agents have the potential to reshape the treatment landscape for a range of large market, IgG-mediated diseases.”

For earnings history and earnings-related data on Momenta Phama (MNTA) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Earnings, Management Comments

Related Entities

Earnings